On April 8, 1986—36 years ago today—the Multidisciplinary Association for Psychedelic Studies (MAPS) was founded by Rick Doblin, Ph.D., as a non-profit organization to fulfill the need to broaden psychedelic …
MAPS Europe is delighted to announce that on March 23, 2022, the first site in the United Kingdom was activated and will begin screening patients in our open-label Phase 2 study of MDMA-assisted therapy …
On March 22, 2022, all study sites have met the criteria to provide treatment in the cross-over extension study for MAPS-sponsored Phase 3 trials of MDMA-assisted therapy for posttraumatic stress disorder …
Our Expanded Access Program study site at Sage Integrative Health in Berkeley, California, began screening participants for MDMA-assisted therapy for PTSD in early March. Our multi-site expanded access …
On March 17, 2022, MAPS submitted a complete response to the U.S. Food and Drug Administration (FDA) addressing the partial clinical hold issues in the MAPS-sponsored Study MPG1. The response upheld that …
Dr. Stephen Bright and a team of researchers at Edith Cowan University in Joondalup, Western Australia, are conducting a study to assess the safety and effect of manualised MDMA-assisted therapy for the …
The 2022 training schedule has been posted on the training website, including options for a blended (online/in person) training format and an entirely virtual training format. Blended format cohorts: …
We encourage you to read and follow maps.org/safety for detailed information regardingMAPS Code of Ethics for Psychedelic Psychotherapyand our practices to create a culture of safety in psychedelic therapy. …
On February 28, 2022, the U.S. Food and Drug Administration (FDA) placed Study MPG1 on partial clinical hold, preventing the study from being initiated. FDA highlighted their concerns in the Partial Clinical …
In January 2022, over 1,250 donors gave $1,806,697 in donations and pledges. We are so grateful to these supporters who advance our shared vision of creating safe and legal opportunities for the beneficial …
The 2022 training schedule has been posted on the training website, including options for a blended (online/in person) training format and an entirely virtual training format. Blended format cohorts: April …
On February 15, 2022, the results of our evaluation of MDMA on the startle response in healthy adults was published in the medical journal Psychopharmacology. This randomized, blinded, placebo-controlled …
